Mercado da Bronquiectasia Ásia-Pacífico, por tipo de doença (bronquiectasia FC e bronquiectasia não FC), gravidade (leve a moderada e moderada a grave), tipo (diagnóstico e tratamento), tipo de medicamento (de marca e genéricos), via de administração (Oral, Parentérica e Inalação), Utilizador Final (Hospitais, Clínicas, Assistência Médica Domiciliária e Outros), Canal de Distribuição (Farmácia Hospitalar, Farmácia de Retalho, Farmácia Online, Outros), País (Japão, China, Austrália, Índia, Coreia do Sul, Singapura , Indonésia, Tailândia, Malásia, Filipinas, Vietname e Resto da Ásia-Pacífico) Tendências e previsões da indústria para 2028
Análise e insights de mercado: Mercado de bronquiectasia Ásia-Pacífico
Espera-se que o mercado de bronquiectasia Ásia-Pacífico ganhe crescimento de mercado no período de previsão de 2021 a 2028. A Data Bridge Market Research analisa que o mercado está a crescer com um CAGR de 6,5% no período de previsão de 2021 a 2028 e deverá atingir os 186,19 milhões de USD até 2028. O avanço tecnológico para os testes de doenças e o aumento do número de fumadores e do consumo de álcool são os principais impulsionadores que impulsionaram a procura do mercado no período de previsão.
A bronquiectasia compreende características que a crescente necessidade de produtos seguros e eficazes irá impactar no lançamento de novos produtos pelos fabricantes no mercado que aumentam a sua procura, bem como o aumento do investimento em investigação e desenvolvimento leva ao crescimento do mercado. Estão actualmente a ser realizados vários estudos de investigação que deverão criar uma vantagem competitiva para os fabricantes desenvolverem produtos novos e inovadores para a bronquiectasia, o que deverá proporcionar várias outras oportunidades no mercado da bronquiectasia. No entanto, os recalls de produtos e as complicações no tratamento da bronquiectasia deverão restringir o crescimento do mercado no período de previsão.
A bronquiectasia é uma condição que causa danos nas vias aéreas dos pulmões, ou seja, infeção e inflamação no caminho por onde o ar entra e sai. O muco acumula-se nas vias respiratórias que ficam obstruídas e começam a crescer bactérias nesta região, o que leva à bronquiectasia. Quando este muco se acumula nas vias respiratórias e não é diagnosticado e tratado precocemente, pode causar danos nos pulmões. Esta condição ocorre principalmente na população feminina e nos Estados Unidos registou-se que as crianças com tosse convulsa apresentam geralmente bronquiectasias.
A bronquiectasia pode ser congénita ou adquirida. A adquirida ocorre principalmente em bebés e crianças, enquanto a congénita ocorre em adultos. Fibrose quística , distúrbios de imunodeficiência, aspergilose broncopulmonar alérgica e discinesia ciliar primária são alguns dos fatores de risco para as bronquiectasias. Principalmente os antibióticos e a oxigenoterapia são recomendados pelos médicos e os doentes têm de viver a condição, pois não existe uma cura permanente para a doença.
O relatório de mercado da Bronquiectasia fornece detalhes da quota de mercado, novos desenvolvimentos e análise do pipeline de produtos, impacto dos participantes do mercado doméstico e localizado, analisa as oportunidades em termos de bolsas de receitas emergentes, alterações nas regulamentações do mercado , aprovações de produtos , decisões estratégicas, lançamentos de produtos, geografia expansões e inovações tecnológicas no mercado. Para compreender a análise e o cenário do mercado contacte-nos para um resumo do analista, a nossa equipa irá ajudá-lo a criar uma solução de impacto na receita para atingir o objetivo desejado.
Âmbito e dimensão do mercado de bronquiectasia da Ásia-Pacífico
O mercado da bronquiectasia está segmentado com base no tipo de doença, gravidade, tipo, tipo de medicamento, via de administração, utilizador final e canal de distribuição O crescimento entre segmentos ajuda a analisar nichos de crescimento e estratégias para abordar o mercado e determinar as suas principais áreas de aplicação e a diferença nos seus mercados-alvo.
- Com base no tipo de doença, o mercado das bronquiectasias está segmentado em bronquiectasias não CF e bronquiectasias CF. Em 2021, prevê-se que a bronquiectasia não-FC domine o mercado da bronquiectasia, uma vez que é a forma mais comum de bronquiectasia que afeta a maioria das mulheres e da população adulta.
- Com base na gravidade, o mercado das bronquiectasias está segmentado em ligeiro a moderado e moderado a grave. Em 2021, espera-se que o segmento ligeiro a moderado domine o mercado das bronquiectasias porque a bronquiectasia é uma doença respiratória progressiva que se caracteriza por vias aéreas anormalmente dilatadas, produção excessiva de expetoração e infeções pulmonares recorrentes, entre outros sintomas que podem ser tratados por novos medicamentos e outras terapêuticas.
- Com base no tipo, o mercado da bronquiectasia está segmentado em tratamento e diagnóstico. Em 2021, prevê-se que o segmento de tratamento domine o mercado das bronquiectasias porque a bronquiectasia é a doença crónica de longa duração e a população de doentes afectada é em grande parte dependente de medicamentos para levar uma vida saudável.
- Com base no tipo de medicamento, o mercado da bronquiectasia está segmentado em de marca e genérico . Em 2021, prevê-se que o segmento de marca domine o mercado das bronquiectasias, uma vez que a maioria das empresas está envolvida no fabrico de medicamentos de marca. Além disso, a crescente procura de produtos seguros aumenta a procura de medicamentos de marca entre a população de doentes.
- Com base na via de administração, o mercado das bronquiectasias está segmentado em oral, parentérica e inalatória. Em 2021, espera-se que o segmento da inalação domine o mercado da bronquiectasia porque a bronquiectasia é uma doença inflamatória associada ao pulmão que pode ser tratada rapidamente com medicamentos direcionados diretamente para as vias aéreas pulmonares.
- On the basis of end user, the bronchiectasis market is segmented into hospitals, clinics, home healthcare, and others. In 2021, hospitals segment is dominating the bronchiectasis market because hospitals have advanced diagnostic tools used for accurate diagnosis of bronchiectasis. Moreover skilled professionals at hospitals allow effective intravenous drug delivery which acts as another factor boosting the market growth.
- On the basis of distribution channel, the bronchiectasis market is segmented into hospital pharmacy, retail pharmacy and online pharmacy. In 2021, hospital pharmacy is expected to dominate the bronchiectasis market as hospital pharmacy have has wide range of products as per the patients need and demand.
Bronchiectasis Market Country Level Analysis
The bronchiectasis market is analyzed and market size information is provided on the basis of disease type, severity, type, drugs type, route of administration, end user and distribution channel.
The countries covered in the bronchiectasis market report are the Japan, China, Australia, India, South Korea, Singapore, Indonesia, Thailand, Malaysia, Philippines, Vietnam and Rest of Asia-Pacific.
Treatment segment in Asia-Pacific region is expected to grow with the highest growth rate in the forecast period of 2021 to 2028 because bronchiectasis is the life-long disease and required continuous treatment. The overall treatment cost for the bronchiectasis is quite high and now consider in some reimbursement policies. Japan is leading the growth of the Asia-Pacific market and treatment segment is dominating in this country due to technological advancement for the diagnosis and treatment of respiratory diseases.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, regulatory acts and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, presence and availability of Asia-Pacific brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of sales channels are considered while providing forecast analysis of the country data.
Technological Advancement for Disease Testing and Increase in Research Regarding the Bronchiectasis Disease are Boosting the Market Growth of Bronchiectasis
Bronchiectasis market also provides you with detailed market analysis for every country growth in bronchiectasis industry with bronchiectasis drugs sales, impact of advancement in the bronchiectasis technology and changes in regulatory scenarios with their support for the bronchiectasis market. The data is available for historic period 2011 to 2019.
Competitive Landscape and Bronchiectasis Market Share Analysis
O cenário competitivo do mercado da Bronquiectasia fornece detalhes por concorrente. Os detalhes incluídos são a visão geral da empresa, finanças da empresa, receitas geradas, potencial de mercado, investimento em investigação e desenvolvimento, novas iniciativas de mercado, localizações e instalações de produção, pontos fortes e fracos da empresa, lançamento de produtos, pipelines de testes de produtos, aprovações de produtos, patentes, largura do produto e respiração, domínio da aplicação, curva da linha de vida da tecnologia. Os dados acima fornecidos estão apenas relacionados com o foco da empresa relacionado com o mercado das bronquiectasias.
As principais empresas que lidam com a bronquiectasia são a Abbott, HERSILL, Inogen, Inc., Boehringer Ingelheim International GmbH, Medline Industries, Inc, Ache Laboratories Farmaceuticos SA, Janssen Pharmaceuticals, Inc.), GlaxoSmithKline plc., AstraZeneca, Pfizer Inc., Merck Sharp & Dohme Corp., uma subsidiária da Merck & Co., Inc., Novartis AG, Sun Pharmaceutical Industries Ltd., Bayer AG, Dr. e Cipla Inc., entre outras.
Muitos lançamentos e acordos de produtos são também iniciados pelas empresas de todo o mundo que também estão a acelerar o mercado das bronquiectasias.
- Em dezembro de 2018, a AstraZeneca recebeu aprovação para o Bevespi Aerosphere (glicopirrónio/fumarato de formoterol) indicado para o tratamento de sintomas graves associados à DPOC. Este produto já recebeu aprovação das autoridades reguladoras do Canadá, EUA, Austrália, Taiwan e Turquia. Esta nova homologação potenciou as vendas do produto o que impactou positivamente o volume de negócios da empresa.
- Em fevereiro de 2018, a GlaxoSmithKline plc. lançou o Flunase, no Japão. A flunase é o primeiro tratamento à base de propionato de fluticasona lançado no Japão e está indicado no alívio de sintomas inflamatórios associados a problemas respiratórios. O lançamento deste produto permitiu assim à empresa satisfazer a procura não satisfeita dos pacientes que sofrem de bronquiectasia no Japão e impulsionou a receita da empresa através do aumento positivo das vendas do produto.
A colaboração, o lançamento de produtos, a expansão do negócio, a premiação e reconhecimento, as joint ventures e outras estratégias do player de mercado estão a potenciar o mercado da empresa no mercado das bronquiectasias, o que também proporciona o benefício para a organização melhorar a sua oferta para as bronquiectasias.
SKU-
Obtenha acesso online ao relatório sobre a primeira nuvem de inteligência de mercado do mundo
- Painel interativo de análise de dados
- Painel de análise da empresa para oportunidades de elevado potencial de crescimento
- Acesso de analista de pesquisa para personalização e customização. consultas
- Análise da concorrência com painel interativo
- Últimas notícias, atualizações e atualizações Análise de tendências
- Aproveite o poder da análise de benchmark para um rastreio abrangente da concorrência
Índice
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF ASIA PACIFIC BRONCHIECTASIS MARKET
1.4 LIMITATIONS
1.5 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 MARKETS COVERED
2.2 GEOGRAPHICAL SCOPE
2.3 YEARS CONSIDERED FOR THE STUDY
2.4 CURRENCY AND PRICING
2.5 DBMR TRIPOD DATA VALIDATION MODEL
2.6 MULTIVARIATE MODELLING
2.7 DISEASE TYPE LIFELINE CURVE
2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.9 DBMR MARKET POSITION GRID
2.1 VENDOR SHARE ANALYSIS
2.11 MARKET DRUGS TYPE COVERAGE GRID
2.12 SECONDARY SOURCES
2.13 ASSUMPTIONS
3 EXECUTIVE SUMMARY
4 PIPELINE ANALYSIS
5 ASIA PACIFIC BRONCHIECTASIS MARKET: LAWS AND REGULATIONS
6 EPIDEMIOLOGY
7 MARKET OVERVIEW
7.1 DRIVERS
7.1.1 RISING PATIENT POPULATION SUFFERING FROM BRONCHIECTASIS
7.1.2 GROWING GERIATRIC POPULATION
7.1.3 RISING NUMBER OF SMOKERS AND CONSUMPTION OF ALCOHOL
7.1.4 TECHNOLOGICAL ADVANCEMENT FOR DISEASE TESTING
7.1.5 GROWING DIAGNOSTIC RATE
7.2 RESTRAINTS
7.2.1 HIGH COST OF DIAGNOSTIC TOOLS
7.2.2 PRODUCT RECALLS
7.2.3 INAPPROPRIATE REIMBURSEMENT POLICIES
7.3 OPPORTUNITIES
7.3.1 RISING AWARENESS FOR PREVENTION OF BRONCHIECTASIS IN PRIMARY AND SECONDARY CARE
7.3.2 INCREASING HEALTHCARE EXPENDITURE
7.3.3 INCREASE IN RESEARCH REGARDING THE BRONCHIECTASIS DISEASE
7.3.4 AVAILABILITY OF GENERIC DRUGS IN UNDERDEVELOPED AND DEVELOPING COUNTRIES
7.4 CHALLENGES
7.4.1 COMPLICATIONS IN THE TREATMENT OF BRONCHIECTASIS
7.4.2 LACK OF SKILLED PROFESSIONALS
7.4.3 DIAGNOSITIC CHALLENGES
8 IMPACT OF COVID-19
8.1 PRICE IMPACT
8.2 IMPACT ON DEMAND
8.3 IMPACT ON SUPPLY CHAIN
8.4 STRATEGIC DECISIONS FOR MANUFACTURERS
8.5 CONCLUSION
9 ASIA PACIFIC BRONCHIECTASIS MARKET, BY DISEASE TYPE
9.1 OVERVIEW
9.2 NON-CF BRONCHIECTASIS
9.3 CF BRONCHIECTASIS
10 ASIA PACIFIC BRONCHIECTASIS MARKET, BY SEVERITY
10.1 OVERVIEW
10.2 MILD TO MODERATE
10.3 MODERATE TO SEVERE
11 ASIA PACIFIC BRONCHIECTASIS MARKET, BY TYPE
11.1 OVERVIEW
11.2 TREATMENT
11.2.1 ANTIBIOTICS
11.2.1.1 MACROLIDE
11.2.1.1.1 AZITHROMYCIN
11.2.1.1.2 CLARITHROMYCIN
11.2.1.1.3 OTHERS
11.2.1.2 AMOXICILLIN
11.2.1.3 CEPHALOSPORIN
11.2.1.3.1 SECOND-GENERATION CEPHALOSPORIN
11.2.1.3.2 THIRD-GENERATION CEPHALOSPORIN
11.2.1.4 AMINOGLYCOSIDE
11.2.1.4.1 GENTAMICIN
11.2.1.4.2 TOBRAMYCIN
11.2.1.5 FLUOROQUINOLONE
11.2.1.6 TETRACYCLINS
11.2.1.7 TRIMETHOPRIM-SULFAMETHOXAZOLE
11.2.1.8 COMBINATION THERAPY
11.2.2 CORTICOSTEROIDS
11.2.2.1 BUDESONIDE
11.2.2.2 FLUTICASONE
11.2.2.3 MOMETASONE
11.2.2.4 FLUNISOLIDE
11.2.2.5 OTHERS
11.2.3 BRONCHODILATORS
11.2.3.1 LONG-ACTING BRONCHODILATORS
11.2.3.1.1 FORMOTEROL
11.2.3.1.2 TIOTROPIUM
11.2.3.1.3 SALMETEROL
11.2.3.1.4 OTHERS
11.2.3.2 SHORT-ACTING BRONCHODILATORS
11.2.3.2.1 ALBUTEROL
11.2.3.2.2 LEVALBUTEROL
11.2.3.2.3 OTHERS
11.2.4 MUCUS THINNING MEDICINE
11.2.4.1 CARBOCISTEINE
11.2.4.2 BROMHEXINE
11.2.4.3 OTHERS
11.2.5 AIRWAY CLEARANCE DEVICES
11.2.5.1 OSCILLATING POSITIVE EXPIRATORY PRESSURE (PEP)
11.2.5.2 INTRAPULMONARY PERCUSSIVE VENTILATION (IPV)
11.2.5.3 POSTURAL DRAINAGE
11.2.5.4 OTHERS
11.2.6 OXYGEN THERAPY
11.2.6.1 OXYGEN CONCENTRATORS
11.2.6.2 COMPRESSED GAS OXYGEN
11.2.6.3 LIQUID OXYGEN
11.2.7 SURGERY
11.2.7.1 BRONCHOSCOPY
11.2.7.2 LUNG TRANSPLANT
11.2.8 OTHERS
11.3 DIAGNOSIS
11.3.1 CHEST CT SCAN
11.3.2 SPUTUM TEST
11.3.3 PULMONARY FUNCTION TEST
11.3.4 X-RAY
11.3.5 OTHERS
12 ASIA PACIFIC BRONCHIECTASIS MARKET, BY DRUGS TYPE
12.1 OVERVIEW
12.2 BRANDED
12.3 GENERICS
13 ASIA PACIFIC BRONCHIECTASIS MARKET, BY ROUTE OF ADMINISTRATION
13.1 OVERVIEW
13.2 INHALATION
13.3 ORAL
13.3.1 TABLETS
13.3.2 CAPSULES
13.3.3 OTHERS
13.4 PARENTERAL
13.4.1 INTRAVENOUS
13.4.2 SUBCUTANEOUS
13.4.3 OTHERS
14 ASIA PACIFIC BRONCHIECTASIS MARKET, BY END USER
14.1 OVERVIEW
14.2 HOSPITALS
14.3 CLINICS
14.4 HOME HEALTHCARE
14.5 OTHERS
15 ASIA PACIFIC BRONCHIECTASIS MARKET, BY DISTRIBUTION CHANNEL
15.1 OVERVIEW
15.2 HOSPITAL PHARMACY
15.3 RETAIL PHARMACY
15.4 ONLINE PHARMACY
15.5 OTHERS
16 ASIA PACIFIC BRONCHIECTASIS MARKET BY GEOGRAPHY
16.1 OVERVIEW
16.2 ASIA-PACIFIC
16.2.1 JAPAN
16.2.2 CHINA
16.2.3 INDIA
16.2.4 AUSTRALIA
16.2.5 SOUTH KOREA
16.2.6 SINGAPORE
16.2.7 MALAYSIA
16.2.8 THAILAND
16.2.9 INDONESIA
16.2.10 PHILIPPINES
16.2.11 VIETNAM
16.2.12 REST OF ASIA-PACIFIC
17 ASIA PACIFIC BRONCHIECTASIS MARKET: COMPANY LANDSCAPE
17.1 COMPANY SHARE ANALYSIS: ASIA PACIFIC
18 SWOT
19 COMPANY PROFILES
19.1 ASTRAZENECA
19.1.1 COMPANY SNAPSHOT
19.1.2 REVENUE ANALYSIS
19.1.3 COMPANY SHARE ANALYSIS
19.1.4 PRODUCT PORTFOLIO
19.1.5 RECENT DEVELOPMENTS
19.2 GLAXOSMITHKLINE PLC.
19.2.1 COMPANY SNAPSHOT
19.2.2 REVENUE ANALYSIS
19.2.3 COMPANY SHARE ANALYSIS
19.2.4 PRODUCT PORTFOLIO
19.2.5 RECENT DEVELOPMENTS
19.3 TEVA PHARMACEUTICAL USA INC. (A SUBSIDIARY OF TEVA PHARMACEUTICAL INDUSTRIES LTD.)
19.3.1 COMPANY SNAPSHOT
19.3.2 REVENUE ANALYSIS
19.3.3 COMPANY SHARE ANALYSIS
19.3.4 PRODUCT PORTFOLIO
19.3.5 RECENT DEVELOPMENTS
19.4 MERCK SHARP & DOHME CORP. (A SUBSIDIARY OF MERCK & CO., INC.)
19.4.1 COMPANY SNAPSHOT
19.4.2 REVENUE ANALYSIS
19.4.3 COMPANY SHARE ANALYSIS
19.4.4 PRODUCT PORTFOLIO
19.4.5 RECENT DEVELOPMENTS
19.5 NOVARTIS AG
19.5.1 COMPANY SNAPSHOT
19.5.2 REVENUE ANALYSIS
19.5.3 PRODUCT PORTFOLIO
19.5.4 RECENT DEVELOPMENTS
19.6 ABBOTT
19.6.1 COMPANY SNAPSHOT
19.6.2 REVENUE ANALYSIS
19.6.3 PRODUCT PORTFOLIO
19.6.4 RECENT DEVELOPMENT
19.7 ACHE LABORATORIES FARMACEUTICOS S.A.
19.7.1 COMPANY SNAPSHOT
19.7.2 PRODUCT PORTFOLIO
19.7.3 RECENT DEVELOPMENTS
19.8 BAYER AG
19.8.1 COMPANY SNAPSHOT
19.8.2 REVENUE ANALYSIS
19.8.3 PRODUCT PORTFOLIO
19.8.4 RECENT DEVELOPMENTS
19.9 BOEHRINGER INGELHEIM INTERNATIONAL GMBH
19.9.1 COMPANY SNAPSHOT
19.9.2 REVENUE ANALYSIS
19.9.3 PRODUCT PORTFOLIO
19.9.4 RECENT DEVELOPMENT
19.1 CIPLA INC.
19.10.1 COMPANY SNAPSHOT
19.10.2 REVENUE ANALYSIS
19.10.3 PRODUCT PORTFOLIO
19.10.4 RECENT DEVELOPMENTS
19.11 COVIS PHARMA
19.11.1 COMPANY SNAPSHOT
19.11.2 PRODUCT PORTFOLIO
19.11.3 RECENT DEVELOPMENT
19.12 DR. REDDY’S LABORATORIES LTD.
19.12.1 COMPANY SNAPSHOT
19.12.2 REVENUE ANALYSIS
19.12.3 PRODUCT PORTFOLIO
19.12.4 RECENT DEVELOPMENTS
19.13 ELECTROMED, INC.
19.13.1 COMPANY SNAPSHOT
19.13.2 REVENUE ANALYSIS
19.13.3 PRODUCT PORTFOLIO
19.13.4 RECENT DEVELOPMENTS
19.14 HERSILL
19.14.1 COMPANY SNAPSHOT
19.14.2 PRODUCT PORTFOLIO
19.14.3 RECENT DEVELOPMENTS
19.15 HOME OXYGEN COMPANY
19.15.1 COMPANY SNAPSHOT
19.15.2 PRODUCT PORTFOLIO
19.15.3 RECENT DEVELOPMENT
19.16 HORIZON THERAPEUTICS PLC
19.16.1 COMPANY SNAPSHOT
19.16.2 REVENUE ANALYSIS
19.16.3 PRODUCT PORTFOLIO
19.16.4 RECENT DEVELOPMENT
19.17 INOGEN, INC.
19.17.1 COMPANY SNAPSHOT
19.17.2 REVENUE ANALYSIS
19.17.3 PRODUCT PORTFOLIO
19.17.4 RECENT DEVELOPMENTS
19.18 JANSSEN PHARMACEUTICALS, INC. (A SUBSIDIARY OF JOHNSON & JOHNSON SERVICES, INC.)
19.18.1 COMPANY SNAPSHOT
19.18.2 REVENUE ANALYSIS
19.18.3 PRODUCT PORTFOLIO
19.18.4 RECENT DEVELOPMENT
19.19 MEDLINE INDUSTRIES, INC.
19.19.1 COMPANY SNAPSHOT
19.19.2 PRODUCT PORTFOLIO
19.19.3 RECENT DEVELOPMENTS
19.2 PFIZER INC.
19.20.1 COMPANY SNAPSHOT
19.20.2 REVENUE ANALYSIS
19.20.3 PRODUCT PORTFOLIO
19.20.4 RECENT DEVELOPMENTS
19.21 SUNOVION PHARMACEUTICALS INC. (A SUBSIDIARY OF SUMITOMO DAINIPPON PHARMA CO., LTD.)
19.21.1 COMPANY SNAPSHOT
19.21.2 REVENUE ANALYSIS
19.21.3 PRODUCT PORTFOLIO
19.21.4 RECENT DEVELOPMENTS
19.22 SUN PHARMACEUTICAL INDUSTRIES LTD.
19.22.1 COMPANY SNAPSHOT
19.22.2 REVENUE ANALYSIS
19.22.3 PRODUCT PORTFOLIO
19.22.4 RECENT DEVELOPMENTS
19.23 TRUEDELL MEDICAL INTERNATIONAL
19.23.1 COMPANY SNAPSHOT
19.23.2 PRODUCT PORTFOLIO
19.23.3 RECENT DEVELOPMENTS
19.24 VIATRIS INC.
19.24.1 COMPANY SNAPSHOT
19.24.2 PRODUCT PORTFOLIO
19.24.3 RECENT DEVELOPMENTS
19.25 ZYDUS PHARMACEUTICALS, INC. (A SUBSIDIARY OF ZYDUS CADILA)
19.25.1 COMPANY SNAPSHOT
19.25.2 REVENUE ANALYSIS
19.25.3 PRODUCT PORTFOLIO
19.25.4 RECENT DEVELOPMENTS
20 QUESTIONNAIRE
21 RELATED REPORTS
Lista de Tabela
LIST OF TABLES
TABLE 1 ASIA PACIFIC BRONCHIECTASIS MARKET, PIPELINE ANALYSIS
TABLE 2 REGULATION IMPOSED BY SEVERAL REGULATORY AGENCIES IN DIFFERENT REGIONS
TABLE 3 HEALTHCARE EXPENDITURE IN ASIA-PACIFIC
TABLE 4 THE PRICE OF X-RAY MACHINE
TABLE 5 ASIA PACIFIC BRONCHIECTASIS MARKET, BY DISEASE TYPE, 2019-2028 (USD MILLION)
TABLE 6 ASIA PACIFIC NON-CF BRONCHIECTASIS IN BRONCHIECTASIS MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 7 ASIA PACIFIC CF BRONCHIECTASIS IN BRONCHIECTASIS MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 8 ASIA PACIFIC BRONCHIECTASIS MARKET, BY SEVERITY, 2019-2028 (USD MILLION)
TABLE 9 ASIA PACIFIC MILD TO MODERATE BRONCHIECTASIS IN BRONCHIECTASIS MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 10 ASIA PACIFIC MODERATE TO SEVERE BRONCHIECTASIS IN BRONCHIECTASIS MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 11 ASIA PACIFIC BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 12 ASIA PACIFIC TREATMENT IN BRONCHIECTASIS MARKET, BY REGION, 2017-2028 (USD MILLION)
TABLE 13 ASIA PACIFIC TREATMENT IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 14 ASIA PACIFIC TREATMENT BY ANTIBIOTICS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 15 ASIA PACIFIC TREATMENT BY MACROLIDE ANTIBIOTICS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 16 ASIA PACIFIC TREATMENT BY CEPHALOSPORIN ANTIBIOTICS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 17 ASIA PACIFIC TREATMENT BY AMINOGLYCOSIDE ANTIBIOTICS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 18 ASIA PACIFIC TREATMENT BY CORTICOSTEROIDS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 19 ASIA PACIFIC TREATMENT BY BRONCHODILATORS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 20 ASIA PACIFIC TREATMENT BY LONG-ACTING BRONCHODILATORS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 21 ASIA PACIFIC TREATMENT BY SHORT-ACTING BRONCHODILATORS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 22 ASIA PACIFIC TREATMENT BY MUCUS THINNING MEDICINE IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 23 ASIA PACIFIC TREATMENT BY AIRWAY CLEARANCE DEVICES IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 24 ASIA PACIFIC TREATMENT BY OXYGEN THERAPY IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 25 ASIA PACIFIC TREATMENT BY SURGERY IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 26 ASIA PACIFIC DIAGNOSIS IN BRONCHIECTASIS MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 27 ASIA PACIFIC DIAGNOSIS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 28 ASIA PACIFIC BRONCHIECTASIS MARKET, BY DRUGS TYPE, 2019-2028 (USD MILLION)
TABLE 29 ASIA PACIFIC BRANDED IN BRONCHIECTASIS MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 30 ASIA PACIFIC GENERICS IN BRONCHIECTASIS MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 31 ASIA PACIFIC BRONCHIECTASIS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 32 ASIA PACIFIC INHALATION IN BRONCHIECTASIS MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 33 ASIA PACIFIC ORAL IN BRONCHIECTASIS MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 34 ASIA PACIFIC ORAL ADMINISTRATION IN BRONCHIECTASIS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 35 ASIA PACIFIC PARENTERAL IN BRONCHIECTASIS MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 36 ASIA PACIFIC PARENTERAL ADMINISTRATION IN BRONCHIECTASIS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 37 ASIA PACIFIC BRONCHIECTASIS MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 38 ASIA PACIFIC HOSPITALS IN BRONCHIECTASIS MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 39 ASIA PACIFIC CLINICS IN BRONCHIECTASIS MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 40 ASIA PACIFIC HOME HEALTHCARE IN BRONCHIECTASIS MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 41 ASIA PACIFIC OTHERS IN BRONCHIECTASIS MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 42 ASIA PACIFIC BRONCHIECTASIS MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 43 ASIA PACIFIC HOSPITAL PHARMACY IN BRONCHIECTASIS MARKET, REGION, 2019-2028 (USD MILLION)
TABLE 44 ASIA PACIFIC RETAIL PHARMACY IN BRONCHIECTASIS MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 45 ASIA PACIFIC ONLINE PHARMACY IN BRONCHIECTASIS MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 46 ASIA PACIFIC OTHERS IN BRONCHIECTASIS MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 47 ASIA PACIFIC BRONCHIECTASIS MARKET, BY REGION , 2021-2028 (USD MILLION)
TABLE 48 ASIA-PACIFIC BRONCHIECTASIS MARKET, BY COUNTRY, 2018-2028 (USD MILLION)
TABLE 49 ASIA-PACIFIC BRONCHIECTASIS MARKET, BY DISEASE TYPE, 2019-2028 (USD MILLION)
TABLE 50 ASIA-PACIFIC BRONCHIECTASIS MARKET, BY SEVERITY, 2019-2028 (USD MILLION)
TABLE 51 ASIA-PACIFIC BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 52 ASIA-PACIFIC TREATMENT IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 53 ASIA-PACIFIC TREATMENT BY ANTIBIOTICS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 54 ASIA-PACIFIC TREATMENT BY MACROLIDE ANTIBIOTICS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 55 ASIA-PACIFIC TREATMENT BY CEPHALOSPORIN ANTIBIOTICS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 56 ASIA-PACIFIC TREATMENT BY AMINOGLYCOSIDE ANTIBIOTICS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 57 ASIA-PACIFIC TREATMENT BY CORTICOSTEROIDS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 58 ASIA-PACIFIC TREATMENT BY BRONCHODILATORS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 59 ASIA-PACIFIC TREATMENT BY LONG-ACTING BRONCHODILATORS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 60 ASIA-PACIFIC TREATMENT BY SHORT-ACTING BRONCHODILATORS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 61 ASIA-PACIFIC TREATMENT BY MUCUS THINNING MEDICINE IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 62 ASIA-PACIFIC TREATMENT BY AIRWAY CLEARANCE DEVICES IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 63 ASIA-PACIFIC TREATMENT BY OXYGEN THERAPY IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 64 ASIA-PACIFIC TREATMENT BY SURGERY IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 65 ASIA-PACIFIC DIAGNOSIS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 66 ASIA-PACIFIC BRONCHIECTASIS MARKET, BY DRUGS TYPE, 2019-2028 (USD MILLION)
TABLE 67 ASIA-PACIFIC BRONCHIECTASIS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 68 ASIA-PACIFIC ORAL ADMINISTRATION IN BRONCHIECTASIS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 69 ASIA-PACIFIC PARENTERAL ADMINISTRATION IN BRONCHIECTASIS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 70 ASIA-PACIFIC BRONCHIECTASIS MARKET, BY END USERNEL, 2019-2028 (USD MILLION)
TABLE 71 ASIA-PACIFIC BRONCHIECTASIS MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 72 JAPAN BRONCHIECTASIS MARKET, BY DISEASE TYPE, 2019-2028 (USD MILLION)
TABLE 73 JAPAN BRONCHIECTASIS MARKET, BY SEVERITY, 2019-2028 (USD MILLION)
TABLE 74 JAPAN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 75 JAPAN TREATMENT IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 76 JAPAN TREATMENT BY ANTIBIOTICS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 77 JAPAN TREATMENT BY MACROLIDE ANTIBIOTICS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 78 JAPAN TREATMENT BY CEPHALOSPORIN ANTIBIOTICS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 79 JAPAN TREATMENT BY AMINOGLYCOSIDE ANTIBIOTICS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 80 JAPAN TREATMENT BY CORTICOSTEROIDS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 81 JAPAN TREATMENT BY BRONCHODILATORS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 82 JAPAN TREATMENT BY LONG-ACTING BRONCHODILATORS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 83 JAPAN TREATMENT BY SHORT-ACTING BRONCHODILATORS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 84 JAPAN TREATMENT BY MUCUS THINNING MEDICINE IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 85 JAPAN TREATMENT BY AIRWAY CLEARANCE DEVICES IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 86 JAPAN TREATMENT BY OXYGEN THERAPY IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 87 JAPAN TREATMENT BY SURGERY IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 88 JAPAN DIAGNOSIS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 89 JAPAN BRONCHIECTASIS MARKET, BY DRUGS TYPE, 2019-2028 (USD MILLION)
TABLE 90 JAPAN BRONCHIECTASIS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 91 JAPAN ORAL ADMINISTRATION IN BRONCHIECTASIS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 92 JAPAN PARENTERAL ADMINISTRATION IN BRONCHIECTASIS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 93 JAPAN BRONCHIECTASIS MARKET, BY END USERNEL, 2019-2028 (USD MILLION)
TABLE 94 JAPAN BRONCHIECTASIS MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 95 CHINA BRONCHIECTASIS MARKET, BY DISEASE TYPE, 2019-2028 (USD MILLION)
TABLE 96 CHINA BRONCHIECTASIS MARKET, BY SEVERITY, 2019-2028 (USD MILLION)
TABLE 97 CHINA BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 98 CHINA TREATMENT IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 99 CHINA TREATMENT BY ANTIBIOTICS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 100 CHINA TREATMENT BY MACROLIDE ANTIBIOTICS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 101 CHINA TREATMENT BY CEPHALOSPORIN ANTIBIOTICS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 102 CHINA TREATMENT BY AMINOGLYCOSIDE ANTIBIOTICS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 103 CHINA TREATMENT BY CORTICOSTEROIDS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 104 CHINA TREATMENT BY BRONCHODILATORS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 105 CHINA TREATMENT BY LONG-ACTING BRONCHODILATORS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 106 CHINA TREATMENT BY SHORT-ACTING BRONCHODILATORS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 107 CHINA TREATMENT BY MUCUS THINNING MEDICINE IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 108 CHINA TREATMENT BY AIRWAY CLEARANCE DEVICES IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 109 CHINA TREATMENT BY OXYGEN THERAPY IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 110 CHINA TREATMENT BY SURGERY IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 111 CHINA DIAGNOSIS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 112 CHINA BRONCHIECTASIS MARKET, BY DRUGS TYPE, 2019-2028 (USD MILLION)
TABLE 113 CHINA BRONCHIECTASIS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 114 CHINA ORAL ADMINISTRATION IN BRONCHIECTASIS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 115 CHINA PARENTERAL ADMINISTRATION IN BRONCHIECTASIS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 116 CHINA BRONCHIECTASIS MARKET, BY END USERNEL, 2019-2028 (USD MILLION)
TABLE 117 CHINA BRONCHIECTASIS MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 118 INDIA BRONCHIECTASIS MARKET, BY DISEASE TYPE, 2019-2028 (USD MILLION)
TABLE 119 INDIA BRONCHIECTASIS MARKET, BY SEVERITY, 2019-2028 (USD MILLION)
TABLE 120 INDIA BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 121 INDIA TREATMENT IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 122 INDIA TREATMENT BY ANTIBIOTICS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 123 INDIA TREATMENT BY MACROLIDE ANTIBIOTICS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 124 INDIA TREATMENT BY CEPHALOSPORIN ANTIBIOTICS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 125 INDIA TREATMENT BY AMINOGLYCOSIDE ANTIBIOTICS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 126 INDIA TREATMENT BY CORTICOSTEROIDS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 127 INDIA TREATMENT BY BRONCHODILATORS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 128 INDIA TREATMENT BY LONG-ACTING BRONCHODILATORS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 129 INDIA TREATMENT BY SHORT-ACTING BRONCHODILATORS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 130 INDIA TREATMENT BY MUCUS THINNING MEDICINE IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 131 INDIA TREATMENT BY AIRWAY CLEARANCE DEVICES IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 132 INDIA TREATMENT BY OXYGEN THERAPY IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 133 INDIA TREATMENT BY SURGERY IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 134 INDIA DIAGNOSIS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 135 INDIA BRONCHIECTASIS MARKET, BY DRUGS TYPE, 2019-2028 (USD MILLION)
TABLE 136 INDIA BRONCHIECTASIS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 137 INDIA ORAL ADMINISTRATION IN BRONCHIECTASIS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 138 INDIA PARENTERAL ADMINISTRATION IN BRONCHIECTASIS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 139 INDIA BRONCHIECTASIS MARKET, BY END USERNEL, 2019-2028 (USD MILLION)
TABLE 140 INDIA BRONCHIECTASIS MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 141 AUSTRALIA BRONCHIECTASIS MARKET, BY DISEASE TYPE, 2019-2028 (USD MILLION)
TABLE 142 AUSTRALIA BRONCHIECTASIS MARKET, BY SEVERITY, 2019-2028 (USD MILLION)
TABLE 143 AUSTRALIA BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 144 AUSTRALIA TREATMENT IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 145 AUSTRALIA TREATMENT BY ANTIBIOTICS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 146 AUSTRALIA TREATMENT BY MACROLIDE ANTIBIOTICS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 147 AUSTRALIA TREATMENT BY CEPHALOSPORIN ANTIBIOTICS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 148 AUSTRALIA TREATMENT BY AMINOGLYCOSIDE ANTIBIOTICS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 149 AUSTRALIA TREATMENT BY CORTICOSTEROIDS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 150 AUSTRALIA TREATMENT BY BRONCHODILATORS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 151 AUSTRALIA TREATMENT BY LONG-ACTING BRONCHODILATORS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 152 AUSTRALIA TREATMENT BY SHORT-ACTING BRONCHODILATORS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 153 AUSTRALIA TREATMENT BY MUCUS THINNING MEDICINE IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 154 AUSTRALIA TREATMENT BY AIRWAY CLEARANCE DEVICES IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 155 AUSTRALIA TREATMENT BY OXYGEN THERAPY IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 156 AUSTRALIA TREATMENT BY SURGERY IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 157 AUSTRALIA DIAGNOSIS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 158 AUSTRALIA BRONCHIECTASIS MARKET, BY DRUGS TYPE, 2019-2028 (USD MILLION)
TABLE 159 AUSTRALIA BRONCHIECTASIS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 160 AUSTRALIA ORAL ADMINISTRATION IN BRONCHIECTASIS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 161 AUSTRALIA PARENTERAL ADMINISTRATION IN BRONCHIECTASIS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 162 AUSTRALIA BRONCHIECTASIS MARKET, BY END USERNEL, 2019-2028 (USD MILLION)
TABLE 163 AUSTRALIA BRONCHIECTASIS MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 164 SOUTH KOREA BRONCHIECTASIS MARKET, BY DISEASE TYPE, 2019-2028 (USD MILLION)
TABLE 165 SOUTH KOREAT BRONCHIECTASIS MARKET, BY SEVERITY, 2019-2028 (USD MILLION)
TABLE 166 SOUTH KOREA BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 167 SOUTH KOREA TREATMENT IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 168 SOUTH KOREA TREATMENT BY ANTIBIOTICS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 169 SOUTH KOREA TREATMENT BY MACROLIDE ANTIBIOTICS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 170 SOUTH KOREA TREATMENT BY CEPHALOSPORIN ANTIBIOTICS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 171 SOUTH KOREA TREATMENT BY AMINOGLYCOSIDE ANTIBIOTICS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 172 SOUTH KOREA TREATMENT BY CORTICOSTEROIDS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 173 SOUTH KOREA TREATMENT BY BRONCHODILATORS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 174 SOUTH KOREA TREATMENT BY LONG-ACTING BRONCHODILATORS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 175 SOUTH KOREA TREATMENT BY SHORT-ACTING BRONCHODILATORS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 176 SOUTH KOREA TREATMENT BY MUCUS THINNING MEDICINE IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 177 SOUTH KOREA TREATMENT BY AIRWAY CLEARANCE DEVICES IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 178 SOUTH KOREA TREATMENT BY OXYGEN THERAPY IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 179 SOUTH KOREA TREATMENT BY SURGERY IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 180 SOUTH KOREA DIAGNOSIS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 181 SOUTH KOREA BRONCHIECTASIS MARKET, BY DRUGS TYPE, 2019-2028 (USD MILLION)
TABLE 182 SOUTH KOREA BRONCHIECTASIS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 183 SOUTH KOREA ORAL ADMINISTRATION IN BRONCHIECTASIS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 184 SOUTH KOREA PARENTERAL ADMINISTRATION IN BRONCHIECTASIS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 185 SOUTH KOREA BRONCHIECTASIS MARKET, BY END USERNEL, 2019-2028 (USD MILLION)
TABLE 186 SOUTH KOREA BRONCHIECTASIS MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 187 SINGAPORE BRONCHIECTASIS MARKET, BY DISEASE TYPE, 2019-2028 (USD MILLION)
TABLE 188 SINGAPORE BRONCHIECTASIS MARKET, BY SEVERITY, 2019-2028 (USD MILLION)
TABLE 189 SINGAPORE BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 190 SINGAPORE TREATMENT IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 191 SINGAPORE TREATMENT BY ANTIBIOTICS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 192 SINGAPORE TREATMENT BY MACROLIDE ANTIBIOTICS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 193 SINGAPORE TREATMENT BY CEPHALOSPORIN ANTIBIOTICS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 194 SINGAPORE TREATMENT BY AMINOGLYCOSIDE ANTIBIOTICS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 195 SINGAPORE TREATMENT BY CORTICOSTEROIDS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 196 SINGAPORE TREATMENT BY BRONCHODILATORS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 197 SINGAPORE TREATMENT BY LONG-ACTING BRONCHODILATORS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 198 SINGAPORE TREATMENT BY SHORT-ACTING BRONCHODILATORS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 199 SINGAPORE TREATMENT BY MUCUS THINNING MEDICINE IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 200 SINGAPORE TREATMENT BY AIRWAY CLEARANCE DEVICES IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 201 SINGAPORE TREATMENT BY OXYGEN THERAPY IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 202 SINGAPORE TREATMENT BY SURGERY IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 203 SINGAPORE DIAGNOSIS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 204 SINGAPORE BRONCHIECTASIS MARKET, BY DRUGS TYPE, 2019-2028 (USD MILLION)
TABLE 205 SINGAPORE BRONCHIECTASIS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 206 SINGAPORE ORAL ADMINISTRATION IN BRONCHIECTASIS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 207 SINGAPORE PARENTERAL ADMINISTRATION IN BRONCHIECTASIS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 208 SINGAPORE BRONCHIECTASIS MARKET, BY END USERNEL, 2019-2028 (USD MILLION)
TABLE 209 SINGAPORE BRONCHIECTASIS MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 210 MALAYSIA BRONCHIECTASIS MARKET, BY DISEASE TYPE, 2019-2028 (USD MILLION)
TABLE 211 MALAYSIA BRONCHIECTASIS MARKET, BY SEVERITY, 2019-2028 (USD MILLION)
TABLE 212 MALAYSIA BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 213 MALAYSIA TREATMENT IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 214 MALAYSIA TREATMENT BY ANTIBIOTICS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 215 MALAYSIA TREATMENT BY MACROLIDE ANTIBIOTICS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 216 MALAYSIA TREATMENT BY CEPHALOSPORIN ANTIBIOTICS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 217 MALAYSIA TREATMENT BY AMINOGLYCOSIDE ANTIBIOTICS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 218 MALAYSIA TREATMENT BY CORTICOSTEROIDS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 219 MALAYSIA TREATMENT BY BRONCHODILATORS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 220 MALAYSIA TREATMENT BY LONG-ACTING BRONCHODILATORS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 221 MALAYSIA TREATMENT BY SHORT-ACTING BRONCHODILATORS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 222 MALAYSIA TREATMENT BY MUCUS THINNING MEDICINE IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 223 MALAYSIA TREATMENT BY AIRWAY CLEARANCE DEVICES IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 224 MALAYSIA TREATMENT BY OXYGEN THERAPY IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 225 MALAYSIA TREATMENT BY SURGERY IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 226 MALAYSIA DIAGNOSIS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 227 MALAYSIA BRONCHIECTASIS MARKET, BY DRUGS TYPE, 2019-2028 (USD MILLION)
TABLE 228 MALAYSIA BRONCHIECTASIS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 229 MALAYSIA ORAL ADMINISTRATION IN BRONCHIECTASIS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 230 MALAYSIA PARENTERAL ADMINISTRATION IN BRONCHIECTASIS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 231 MALAYSIA BRONCHIECTASIS MARKET, BY END USERNEL, 2019-2028 (USD MILLION)
TABLE 232 MALAYSIA BRONCHIECTASIS MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 233 THAILAND BRONCHIECTASIS MARKET, BY DISEASE TYPE, 2019-2028 (USD MILLION)
TABLE 234 THAILAND BRONCHIECTASIS MARKET, BY SEVERITY, 2019-2028 (USD MILLION)
TABLE 235 THAILAND BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 236 THAILAND TREATMENT IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 237 THAILAND TREATMENT BY ANTIBIOTICS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 238 THAILAND TREATMENT BY MACROLIDE ANTIBIOTICS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 239 THAILAND TREATMENT BY CEPHALOSPORIN ANTIBIOTICS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 240 THAILAND TREATMENT BY AMINOGLYCOSIDE ANTIBIOTICS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 241 THAILAND TREATMENT BY CORTICOSTEROIDS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 242 THAILAND TREATMENT BY BRONCHODILATORS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 243 THAILAND TREATMENT BY LONG-ACTING BRONCHODILATORS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 244 THAILAND TREATMENT BY SHORT-ACTING BRONCHODILATORS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 245 THAILAND TREATMENT BY MUCUS THINNING MEDICINE IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 246 THAILAND TREATMENT BY AIRWAY CLEARANCE DEVICES IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 247 THAILAND TREATMENT BY OXYGEN THERAPY IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 248 THAILAND TREATMENT BY SURGERY IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 249 THAILAND DIAGNOSIS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 250 THAILAND BRONCHIECTASIS MARKET, BY DRUGS TYPE, 2019-2028 (USD MILLION)
TABLE 251 THAILAND BRONCHIECTASIS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 252 THAILAND ORAL ADMINISTRATION IN BRONCHIECTASIS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 253 THAILAND PARENTERAL ADMINISTRATION IN BRONCHIECTASIS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 254 THAILAND BRONCHIECTASIS MARKET, BY END USERNEL, 2019-2028 (USD MILLION)
TABLE 255 THAILAND BRONCHIECTASIS MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 256 INDONESIA BRONCHIECTASIS MARKET, BY DISEASE TYPE, 2019-2028 (USD MILLION)
TABLE 257 INDONESIA BRONCHIECTASIS MARKET, BY SEVERITY, 2019-2028 (USD MILLION)
TABLE 258 INDONESIA BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 259 INDONESIA TREATMENT IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 260 INDONESIA TREATMENT BY ANTIBIOTICS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 261 INDONESIA TREATMENT BY MACROLIDE ANTIBIOTICS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 262 INDONESIA TREATMENT BY CEPHALOSPORIN ANTIBIOTICS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 263 INDONESIA TREATMENT BY AMINOGLYCOSIDE ANTIBIOTICS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 264 INDONESIA TREATMENT BY CORTICOSTEROIDS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 265 INDONESIA TREATMENT BY BRONCHODILATORS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 266 INDONESIA TREATMENT BY LONG-ACTING BRONCHODILATORS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 267 INDONESIA TREATMENT BY SHORT-ACTING BRONCHODILATORS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 268 INDONESIA TREATMENT BY MUCUS THINNING MEDICINE IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 269 INDONESIA TREATMENT BY AIRWAY CLEARANCE DEVICES IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 270 INDONESIA TREATMENT BY OXYGEN THERAPY IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 271 INDONESIA TREATMENT BY SURGERY IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 272 INDONESIA DIAGNOSIS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 273 INDONESIA BRONCHIECTASIS MARKET, BY DRUGS TYPE, 2019-2028 (USD MILLION)
TABLE 274 INDONESIA BRONCHIECTASIS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 275 INDONESIA ORAL ADMINISTRATION IN BRONCHIECTASIS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 276 INDONESIA PARENTERAL ADMINISTRATION IN BRONCHIECTASIS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 277 INDONESIA BRONCHIECTASIS MARKET, BY END USERNEL, 2019-2028 (USD MILLION)
TABLE 278 INDONESIA BRONCHIECTASIS MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 279 PHILIPPINES BRONCHIECTASIS MARKET, BY DISEASE TYPE, 2019-2028 (USD MILLION)
TABLE 280 PHILIPPINES BRONCHIECTASIS MARKET, BY SEVERITY, 2019-2028 (USD MILLION)
TABLE 281 PHILIPPINES BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 282 PHILIPPINES TREATMENT IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 283 PHILIPPINES TREATMENT BY ANTIBIOTICS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 284 PHILIPPINES TREATMENT BY MACROLIDE ANTIBIOTICS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 285 PHILIPPINES TREATMENT BY CEPHALOSPORIN ANTIBIOTICS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 286 PHILIPPINES TREATMENT BY AMINOGLYCOSIDE ANTIBIOTICS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 287 PHILIPPINES TREATMENT BY CORTICOSTEROIDS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 288 PHILIPPINES TREATMENT BY BRONCHODILATORS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 289 PHILIPPINES TREATMENT BY LONG-ACTING BRONCHODILATORS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 290 PHILIPPINES TREATMENT BY SHORT-ACTING BRONCHODILATORS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 291 PHILIPPINES TREATMENT BY MUCUS THINNING MEDICINE IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 292 PHILIPPINES TREATMENT BY AIRWAY CLEARANCE DEVICES IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 293 PHILIPPINES TREATMENT BY OXYGEN THERAPY IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 294 PHILIPPINES TREATMENT BY SURGERY IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 295 PHILIPPINES DIAGNOSIS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 296 PHILIPPINES BRONCHIECTASIS MARKET, BY DRUGS TYPE, 2019-2028 (USD MILLION)
TABLE 297 PHILIPPINES BRONCHIECTASIS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 298 PHILIPPINES ORAL ADMINISTRATION IN BRONCHIECTASIS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 299 PHILIPPINES PARENTERAL ADMINISTRATION IN BRONCHIECTASIS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 300 PHILIPPINES BRONCHIECTASIS MARKET, BY END USERNEL, 2019-2028 (USD MILLION)
TABLE 301 PHILIPPINES BRONCHIECTASIS MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 302 VIETNAM BRONCHIECTASIS MARKET, BY DISEASE TYPE, 2019-2028 (USD MILLION)
TABLE 303 VIETNAM BRONCHIECTASIS MARKET, BY SEVERITY, 2019-2028 (USD MILLION)
TABLE 304 VIETNAM BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 305 VIETNAM TREATMENT IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 306 VIETNAM TREATMENT BY ANTIBIOTICS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 307 VIETNAM TREATMENT BY MACROLIDE ANTIBIOTICS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 308 VIETNAM TREATMENT BY CEPHALOSPORIN ANTIBIOTICS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 309 VIETNAM TREATMENT BY AMINOGLYCOSIDE ANTIBIOTICS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 310 VIETNAM TREATMENT BY CORTICOSTEROIDS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 311 VIETNAM TREATMENT BY BRONCHODILATORS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 312 VIETNAM TREATMENT BY LONG-ACTING BRONCHODILATORS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 313 VIETNAM TREATMENT BY SHORT-ACTING BRONCHODILATORS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 314 VIETNAM TREATMENT BY MUCUS THINNING MEDICINE IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 315 VIETNAM TREATMENT BY AIRWAY CLEARANCE DEVICES IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 316 VIETNAM TREATMENT BY OXYGEN THERAPY IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 317 VIETNAM TREATMENT BY SURGERY IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 318 VIETNAM DIAGNOSIS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 319 VIETNAM BRONCHIECTASIS MARKET, BY DRUGS TYPE, 2019-2028 (USD MILLION)
TABLE 320 VIETNAM BRONCHIECTASIS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 321 VIETNAM ORAL ADMINISTRATION IN BRONCHIECTASIS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 322 VIETNAM PARENTERAL ADMINISTRATION IN BRONCHIECTASIS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 323 VIETNAM BRONCHIECTASIS MARKET, BY END USERNEL, 2019-2028 (USD MILLION)
TABLE 324 VIETNAM BRONCHIECTASIS MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 325 REST OF ASIA-PACIFIC BRONCHIECTASIS MARKET, BY DISEASE TYPE, 2019-2028 (USD MILLION)
Lista de Figura
LIST OF FIGURES
FIGURE 1 ASIA PACIFIC BRONCHIECTASIS MARKET: SEGMENTATION
FIGURE 2 ASIA PACIFIC BRONCHIECTASIS MARKET : DATA TRIANGULATION
FIGURE 3 ASIA PACIFIC BRONCHIECTASIS MARKET: DROC ANALYSIS
FIGURE 4 ASIA PACIFIC BRONCHIECTASIS MARKET: ASIA PACIFIC VS REGIONAL MARKET ANALYSIS
FIGURE 5 ASIA PACIFIC BRONCHIECTASIS MARKET: COMPANY RESEARCH ANALYSIS
FIGURE 6 ASIA PACIFIC BRONCHIECTASIS MARKET: MULTIVARIATE MODELLING
FIGURE 7 ASIA PACIFIC BRONCHIECTASIS MARKET: INTERVIEW DEMOGRAPHICS
FIGURE 8 ASIA PACIFIC BRONCHIECTASIS MARKET: DBMR MARKET POSITION GRID
FIGURE 9 ASIA PACIFIC BRONCHIECTASIS MARKET: VENDOR SHARE ANALYSIS
FIGURE 10 ASIA PACIFIC BRONCHIECTASIS MARKET: MARKET DRUGS TYPE COVERAGE GRID
FIGURE 11 ASIA PACIFIC BRONCHIECTASIS MARKET: SEGMENTATION
FIGURE 12 RISING PATIENT POPULATION SUFFERING FROM BRONCHIECTASIS IS DRIVING THE ASIA PACIFIC BRONCHIECTASIS MARKET IN THE FORECAST PERIOD OF 2021 TO 2028
FIGURE 13 NON-CF BRONCHIECTASIS SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE ASIA PACIFIC BRONCHIECTASIS MARKET IN 2021 & 2028
FIGURE 14 DRIVERS, RESTRAINTS, OPPORTUNITIES AND CHALLENGES OF ASIA PACIFIC BRONCHIECTASIS MARKET
FIGURE 15 NUMBER OF PERSONS AGED 60 YEARS ACROSS SEVERAL REGIONS IN 2017 AND 2050
FIGURE 16 PREVALENCE OF BRONCHIECTASIS BY AGE IN KOREA POPULATION (2019)
FIGURE 17 HEALTH SPENDING BY MAJOR SOURCES OF FUNDS
FIGURE 18 ASIA PACIFIC BRONCHIECTASIS MARKET: BY DISEASE TYPE, 2021
FIGURE 19 ASIA PACIFIC BRONCHIECTASIS MARKET: BY DISEASE TYPE, 2019-2028 (USD MILLION)
FIGURE 20 ASIA PACIFIC BRONCHIECTASIS MARKET: BY DISEASE TYPE, CAGR (2021-2028)
FIGURE 21 ASIA PACIFIC BRONCHIECTASIS MARKET: BY DISEASE TYPE, LIFELINE CURVE
FIGURE 22 ASIA PACIFIC BRONCHIECTASIS MARKET: BY SEVERITY, 2021
FIGURE 23 ASIA PACIFIC BRONCHIECTASIS MARKET: BY SEVERITY, 2019-2028 (USD MILLION)
FIGURE 24 ASIA PACIFIC BRONCHIECTASIS MARKET: BY SEVERITY, CAGR(2021-2028)
FIGURE 25 ASIA PACIFIC BRONCHIECTASIS MARKET: BY SEVERITY, LIFELINE CURVE
FIGURE 26 ASIA PACIFIC BRONCHIECTASIS MARKET: BY TYPE, 2021
FIGURE 27 ASIA PACIFIC BRONCHIECTASIS MARKET: BY TYPE, 2019-2028 (USD MILLION)
FIGURE 28 ASIA PACIFIC BRONCHIECTASIS MARKET: BY TYPE, CAGR (2021-2028)
FIGURE 29 ASIA PACIFIC BRONCHIECTASIS MARKET: BY TYPE, LIFELINE CURVE
FIGURE 30 ASIA PACIFIC BRONCHIECTASIS MARKET: BY DRUGS TYPE, 2021
FIGURE 31 ASIA PACIFIC BRONCHIECTASIS MARKET: BY DRUGS TYPE, 2019-2028 (USD MILLION)
FIGURE 32 ASIA PACIFIC BRONCHIECTASIS MARKET: BY DRUGS TYPE, CAGR (2021-2028)
FIGURE 33 ASIA PACIFIC BRONCHIECTASIS MARKET: BY DRUGS TYPE, LIFELINE CURVE
FIGURE 34 ASIA PACIFIC BRONCHIECTASIS MARKET: BY ROUTE OF ADMINISTRATION, 2021
FIGURE 35 ASIA PACIFIC BRONCHIECTASIS MARKET: BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
FIGURE 36 ASIA PACIFIC BRONCHIECTASIS MARKET: BY ROUTE OF ADMINISTRATION, CAGR (2021-2028)
FIGURE 37 ASIA PACIFIC BRONCHIECTASIS MARKET: BY ROUTE OF ADMINISTRATION, LIFELINE CURVE
FIGURE 38 ASIA PACIFIC BRONCHIECTASIS MARKET: BY END USER, 2021
FIGURE 39 ASIA PACIFIC BRONCHIECTASIS MARKET: BY END USER, 2019-2028 (USD MILLION)
FIGURE 40 ASIA PACIFIC BRONCHIECTASIS MARKET: BY END USER, CAGR (2021-2028)
FIGURE 41 ASIA PACIFIC BRONCHIECTASIS MARKET: BY END USER, LIFELINE CURVE
FIGURE 42 ASIA PACIFIC BRONCHIECTASIS MARKET: BY DISTRIBUTION CHANNEL, 2021
FIGURE 43 ASIA PACIFIC BRONCHIECTASIS MARKET: BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
FIGURE 44 ASIA PACIFIC BRONCHIECTASIS MARKET: BY DISTRIBUTION CHANNEL, CAGR (2021-2028)
FIGURE 45 ASIA PACIFIC BRONCHIECTASIS MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE
FIGURE 46 ASIA PACIFIC BRONCHIECTASIS MARKET: SNAPSHOT (2020)
FIGURE 47 ASIA PACIFIC BRONCHIECTASIS MARKET: BY COUNTRY (2020)
FIGURE 48 ASIA PACIFIC BRONCHIECTASIS MARKET: BY COUNTRY (2021 & 2028)
FIGURE 49 ASIA PACIFIC BRONCHIECTASIS MARKET: BY COUNTRY (2020 & 2028)
FIGURE 50 ASIA PACIFIC BRONCHIECTASIS MARKET: BY DISEASE TYPE (2021-2028)
FIGURE 51 ASIA-PACIFIC BRONCHIECTASIS MARKET: SNAPSHOT (2020)
FIGURE 52 ASIA-PACIFIC BRONCHIECTASIS MARKET: BY COUNTRY (2020)
FIGURE 53 ASIA-PACIFIC BRONCHIECTASIS MARKET: BY COUNTRY (2021 & 2028)
FIGURE 54 ASIA-PACIFIC BRONCHIECTASIS MARKET: BY COUNTRY (2020 & 2028)
FIGURE 55 ASIA-PACIFIC BRONCHIECTASIS MARKET: BY DISEASE TYPE (2021-2028)
FIGURE 56 ASIA PACIFIC BRONCHIECTASIS MARKET: COMPANY SHARE 2020 (%)
Metodologia de Investigação
A recolha de dados e a análise do ano base são feitas através de módulos de recolha de dados com amostras grandes. A etapa inclui a obtenção de informações de mercado ou dados relacionados através de diversas fontes e estratégias. Inclui examinar e planear antecipadamente todos os dados adquiridos no passado. Da mesma forma, envolve o exame de inconsistências de informação observadas em diferentes fontes de informação. Os dados de mercado são analisados e estimados utilizando modelos estatísticos e coerentes de mercado. Além disso, a análise da quota de mercado e a análise das principais tendências são os principais fatores de sucesso no relatório de mercado. Para saber mais, solicite uma chamada de analista ou abra a sua consulta.
A principal metodologia de investigação utilizada pela equipa de investigação do DBMR é a triangulação de dados que envolve a mineração de dados, a análise do impacto das variáveis de dados no mercado e a validação primária (especialista do setor). Os modelos de dados incluem grelha de posicionamento de fornecedores, análise da linha de tempo do mercado, visão geral e guia de mercado, grelha de posicionamento da empresa, análise de patentes, análise de preços, análise da quota de mercado da empresa, normas de medição, análise global versus regional e de participação dos fornecedores. Para saber mais sobre a metodologia de investigação, faça uma consulta para falar com os nossos especialistas do setor.
Personalização disponível
A Data Bridge Market Research é líder em investigação formativa avançada. Orgulhamo-nos de servir os nossos clientes novos e existentes com dados e análises que correspondem e atendem aos seus objetivos. O relatório pode ser personalizado para incluir análise de tendências de preços de marcas-alvo, compreensão do mercado para países adicionais (solicite a lista de países), dados de resultados de ensaios clínicos, revisão de literatura, mercado remodelado e análise de base de produtos . A análise de mercado dos concorrentes-alvo pode ser analisada desde análises baseadas em tecnologia até estratégias de carteira de mercado. Podemos adicionar quantos concorrentes necessitar de dados no formato e estilo de dados que procura. A nossa equipa de analistas também pode fornecer dados em tabelas dinâmicas de ficheiros Excel em bruto (livro de factos) ou pode ajudá-lo a criar apresentações a partir dos conjuntos de dados disponíveis no relatório.
